USPTO Patent Grants - Therapeutics (A61P)

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

Diaminoguanidine derivative treats bacterial infections in farmed animals

USPTO granted patent US12589085B2 to Guangzhou Insighter Biotechnology Co., Ltd. for a diaminoguanidine derivative compound and feed composition for veterinary use in preventing and treating bacterial infections in farmed animals. The patent covers the compound with R1 as C1-C20 alkyl, applications including reproductive system and skin infections, and includes 11 claims.

USPTO Grants Patent for Sodium Oxybate to Treat Idiopathic Hypersomnia

The United States Patent and Trademark Office (USPTO) has granted patent US12582622B2 to Jazz Pharmaceuticals Ireland Limited for methods of treating idiopathic hypersomnia with sodium oxybate. The patent is effective March 24, 2026.

USPTO Patent Grant for Viral Infection Compounds Targeting Sigma Receptors

The USPTO has granted a patent (US12582619B2) to Thomas Jefferson University for compounds that modulate Sigma receptors to treat viral infections. The patent covers methods for preventing, treating, or ameliorating viral infections using these compounds, potentially in combination with other therapeutic agents.

USPTO Grants Patent for Benzothiazole Compound for Parkinson's and Restless Leg Syndrome

The USPTO has granted a patent (US12583829B2) to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. for a salt of a benzothiazole compound and its crystal form. The patent covers the use of this compound in the preparation of drugs for treating Parkinson's disease and restless leg syndrome.

USPTO Patent Grant for GIP Receptor Antibodies

The USPTO has granted patent US12583930B2 to Crystal Bioscience Inc. for GIP receptor antibodies designed to treat metabolic disorders, specifically those related to glucose metabolism. The patent covers antibodies that bind to and inhibit the human glucose-dependent insulinotropic polypeptide (GIP) receptor.

USPTO Patent Grant: ARDS Treatment with G-CSF Inhibitors

The USPTO has granted patent US12583929B2 to CSL Innovation Pty Ltd for methods of treating acute respiratory distress syndrome (ARDS) using compounds that inhibit G-CSF signaling. The patent covers compounds and their use in manufacturing medicaments for ARDS prevention and treatment.

USPTO Patent for Alzheimer's Treatment Using LRP1/SorLA Antagonist

The USPTO has granted a patent (US12583920B2) to the University of Maryland, Baltimore, for methods and compositions to treat or prevent Alzheimer's disease using LRP1 and/or SorLA antagonists. The patent covers specific therapeutic approaches targeting tau internalization and trafficking in neuronal cells.

USPTO Grants Patent for Flavivirus Cross Neutralizing Antibody

The USPTO has granted patent US12583912B2 for a flavivirus cross-neutralizing antibody developed by the Japan Institute for Health Security. This antibody specifically targets the E protein of flaviviruses, including Zika, dengue, and Japanese encephalitis viruses, and aims to control infection with suppressed Antibody-Dependent Enhancement (ADE).

USPTO Patent Granted for Cognitive Disorder Treatment Compound

The USPTO has granted patent US12583884B2 to AELIS FARMA for a compound, 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one, for use in treating cognitive disorders. The patent filing date was December 18, 2019.

USPTO Patent Grant: Immunopotentiating Amino Acid Mineral Complex

The USPTO has granted a patent (US12583873B2) to BTN CO., LTD. for an amino acid mineral complex with immunopotentiating activity. This complex can be used in compositions for foods, pharmaceuticals, or feeds to enhance immunity or antibody production in humans and animals.

USPTO Patent Grant: Tumor Treatment with Antibodies

The USPTO has granted patent US12582713B2 to Bristol-Myers Squibb Company for methods of treating tumors using pharmaceutical compositions containing anti-PD-1 or anti-PD-L1 antibodies, particularly for subcutaneous delivery. The patent also covers compositions that include an endoglycosidase hydrolase enzyme.

USPTO Grants Patent for Glutathione Trisulfide in Neuroprotection

The USPTO has granted a patent (US12582693B2) to The General Hospital Corporation for methods using glutathione trisulfide (GSSSG) in neuroprotection. The patent covers uses in treating neurodegenerative diseases and reducing ischemic injury risk.

USPTO Patent Grant: Botulinum Toxin for Infertility Treatment

The USPTO has granted a patent (US12582705B2) to CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising botulinum toxin or a salt thereof. This composition is intended to increase endometrial blood flow and improve implantation potential, potentially treating subfertility or infertility.

Patent for Crohn's Disease Indicator and Treatment

The USPTO has granted Washington University a patent (US12582696B2) for methods to treat, select, and monitor inflammatory bowel disease using Debaryomyces species as a biomarker. The treatment involves administering an antifungal compound and detecting fungal DNA or antibodies.

USPTO Patent Grant: Peptides for Treating Glioma Tumors

The USPTO has granted patent US12582695B2 for peptides, compositions, and methods to treat glioma tumors infiltrated with macrophages. The patent was filed on November 27, 2019, and is assigned to Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk.

USPTO Grants Patent for Compounds Inhibiting Protozoan Parasites

The USPTO has granted a patent (US12582694B2) to the University of South Florida for compounds and methods designed to block protozoan parasite invasion and liver-stage development, specifically mentioning Plasmodium falciparum. This patent covers novel therapeutic approaches for treating parasitic infections.

USPTO Patent Grant US12582691B2: Yunnan Baiyao/Xingnaojing for TBI

The USPTO has granted patent US12582691B2 to Lotus Biotech.com LLC for methods of administering Yunnan Baiyao or Xingnaojing to patients with moderate-to-severe traumatic brain injury (TBI) and craniotomy. The patent covers methods for improving postoperative recovery and inhibiting adverse impacts associated with TBI and related neurological conditions.

USPTO Patent Grant: Cancer Treatment Compositions

The USPTO has granted a patent (US12582690B2) to the Korea Institute of Science and Technology for compositions containing Rubus longisepalus var. tozawai extracts for preventing or treating cancer. The patent details specific anticancer efficacy against various cancers, including diffuse-type gastric cancer.

USPTO Grants Patent for Terpenoids in Fibrotic Disease Treatment

The USPTO has granted patent US12582689B2 to ARJIL BIOTECH HOLDING COMPANY LIMITED for a method of treating or preventing fibrotic diseases using terpenoids extracted from Antrodia-camphorate or Anisomeles indica. The patent was granted on March 24, 2026.

USPTO Patent Grant: Bone Fracture Recovery Composition Manufacturing Method

The USPTO has granted a patent (US12582686B2) for a manufacturing method of a composition designed to promote bone fracture recovery. The method involves preparing and processing a specific mixture of herbal and natural ingredients into a liquid extract.

USPTO Patent Grant: Allergy Treatment Compositions

The USPTO has granted patent US12582679B2 to Vedanta Biosciences, Inc. for compositions and methods for treating allergy, including food allergy. The patent covers novel approaches to modulating immune responses and inducing immune tolerance or desensitization.

Immunotherapy Patent for H3K27M Mutation Cancers Issued

The USPTO has issued a new patent (US12582675B2) to The Board of Trustees of the Leland Stanford Junior University for methods of treating cancers harboring an H3K27M mutation using immunotherapy. The patent details the use of immune cells engineered to express GD2-specific chimeric antigen receptors.

Vanadium Compounds Patented for Cancer Treatment

The USPTO has granted a patent (US12582672B2) to The Broad Institute, Inc. for vanadium compositions and methods for treating cancers, particularly those expressing elevated levels of SLC26A2. The patent covers the use of bis(maltolato)oxovanadium(IV) (BMOV) and related compounds.

USPTO Patent Grant: Lignin Solvation for Antimicrobial Therapeutics

The USPTO has granted a patent (US12582670B2) to the University of Florida Research Foundation, Inc. for a method of solvating lignin in aqueous buffers for use in antimicrobial therapeutics. The patent covers aqueous lignin solutions and their applications in treating microbial infections and forming antimicrobial products.

USPTO Patent US12582667B2 for Gastrointestinal Cancer Treatment

The USPTO has granted patent US12582667B2 to The Rockefeller University for compounds and methods to treat metastatic gastrointestinal cancer. The patent details a method involving suppressing the enzymatic activity of DHODH and/or decreasing creatine levels via suppression of the creatine transporter SLC6a8.

USPTO Patent Grant for Low Dose Therapeutic Treatment

The USPTO has granted patent US12582666B2 to Syqe Medical Ltd. for a low dose therapeutic treatment system. The patent covers a system for delivering predetermined amounts of THC, with specific limits on dosage and delivery time, utilizing a decision module and an inhaler device.

USPTO Patent Grant for Injectable Pharmaceutical Compositions by Zoetis

The USPTO has granted patent US12582662B2 to Zoetis Services LLC for injectable pharmaceutical compositions. The patent covers formulations including a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative, designed for effective preservation according to pharmacopoeia standards.

USPTO Grants Patent for RSV Inhibitors

The USPTO has granted a new patent (US12582661B2) to SHANGHAI ARK BIOPHARMACEUTICAL CO., LTD. for a class of respiratory syncytial virus (RSV) inhibitors. The patent, effective March 24, 2026, covers compounds with potential advantages in activity and in vivo exposure compared to existing treatments.

USPTO Patent Grant: Methods Treating Disorders Using CSFIR Inhibitors

The USPTO has granted patent US12582655B2 to Deciphera Pharmaceuticals, LLC for methods of treating cancers and other tumors using CSFIR inhibitors. The patent covers methods related to the proliferation, depletion, or repolarization of tumor-associated macrophages (TAMs).

USPTO Grants Patent for Idiopathic Pulmonary Fibrosis Treatment

The USPTO has granted a patent (US12582653B2) to BEIJING TIDE PHARMACEUTICAL CO., LTD. for a compound and method to treat idiopathic pulmonary fibrosis. The patent covers compounds represented by formula (I) and their pharmaceutically acceptable derivatives.

USPTO Patent for Hair Follicle Regeneration

The USPTO has granted Washington University a patent (US12582649B2) for compositions and methods for hair follicle regeneration using TRPV4 activating agents. The patent aims to treat hair loss conditions such as alopecia and telogen effluvium.

USPTO Patent Grant: Dopamine D3 Agonists for CNS Disorders

The USPTO has granted patent US12582648B2 to Bioprojet Pharma for a method of treating central nervous system disorders, including restless leg syndrome and neurodegenerative diseases, using dopamine D3 partial agonists. The patent details specific applications and classifications related to these therapeutic uses.

USPTO Patent US12582642B2 for Treating Bovine Papillomatosis

The USPTO has granted patent US12582642B2 to KINOPHARMA, INC. for a composition and method to treat bovine papillomatosis. The patent covers compounds represented by Formula (I) or their pharmaceutically acceptable salts.

USPTO Grants Patent for Sulfur Compound in Tumor Treatment

The USPTO has granted patent US12582641B2 to SHANGHAITECH UNIVERSITY for a sulfur-containing compound based on a glutarimide skeleton and its application in treating tumors. The patent filing date was February 25, 2020, and the grant date is March 24, 2026.

Donepezil Topical Formulation Patent for Intradermal Use

The USPTO has granted a patent (US12582637B2) to Arctic Therapeutics HF for a topical formulation of donepezil intended for intradermal application. The patent covers compositions and methods of use for this specific formulation.

USPTO Patent Granted for Cancer Treatment with ERK Inhibitors

The USPTO has granted a patent (US12582635B2) to Biomed Valley Discoveries, Inc. for methods of treating cancer with atypical BRAF mutations using ERK inhibitors. The patent covers compositions, methods for treatment, and identification of suitable patient populations.

USPTO Patent Grant for CAH Treatment Compound

The USPTO has granted patent US12582634B2 to Neurocrine Biosciences, Inc. for a compound and synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent covers specific chemical structures and their preparation, aiming to provide new therapeutic options for this condition.

USPTO Patent Grant for Improving Kidney Function

The USPTO has granted patent US12582631B2 to Chinook Therapeutics, Inc. for methods of improving kidney function. The patent, which includes 36 claims, was filed on August 16, 2022, and granted on March 24, 2026.

USPTO Patent Grant: Dapansutrile for Breast Cancer Treatment

The USPTO has granted patent US12582628B2 to Olatec Therapeutics, Inc. for a method of treating breast cancer using dapansutrile, optionally in combination with a checkpoint inhibitor. The patent covers methods of treatment and has an effective date of March 24, 2026.

Nestle Patent for MCTs Improving Cognitive Function

The USPTO has granted Nestle a patent (US12582627B2) for MCT formulations designed to improve cognitive functions, such as memory and executive function, and to prevent or treat mild cognitive impairment (MCI). The patent specifies daily dosages and composition ratios of medium chain triglycerides, particularly octanoic acid.

USPTO Patent Grant: Composition for Improving Muscle Function

The USPTO has granted patent US12582623B2 to N.V. Nutricia for a composition comprising EPA, MA, and leucine. This composition is intended for the prevention and/or treatment of diseases involving muscle decline or for improving muscle function.

USPTO Patent Granted for Dissociative Disorder Treatment Methods

The USPTO has granted a patent (US12582616B2) to The Board of Trustees of the Leland Stanford Junior University for methods of treating dissociative disorders. The patent covers agents that modulate neural activity in the posteromedial cortex to treat these conditions.

USPTO Grants Patent for ACE Inhibitor and Blood Pressure-Lowering Agent

The USPTO has granted a patent (US12582146B2) to MARUZEN PHARMACEUTICALS CO., LTD. for an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent containing a specific compound. The patent also covers beverages and food products incorporating this compound.

USPTO Patent Grant: Topical Anti-inflammatory Composition with Zileuton

The USPTO has granted a patent (US12582598B2) to QURIENT CO., LTD. for a topical anti-inflammatory pharmaceutical composition comprising Zileuton. The patent covers the composition, its uses, and methods of preparation.

USPTO Patent Grant: B-RAF Kinase Inhibitor Solid Dispersion

The USPTO has granted a patent to BeiGene, Ltd. for a stable solid dispersion of a B-RAF kinase dimer inhibitor, Compound 1. The patent covers the composition, methods of preparation, and uses of this solid dispersion, as well as a crystalline form of Compound 1.

Moderna Cancer Vaccines Patent Grant

The USPTO has granted patent US12582609B2 to ModernaTX, Inc. for cancer ribonucleic acid (RNA) vaccines. The patent covers cancer RNA vaccines, methods of use, and compositions. This grant is a routine notification of intellectual property protection.

Patent: ROS-detonable Nanoclusters for Anti-Restenotic Therapy

The USPTO has granted a patent (US12582613B2) for biomimetic, reactive oxygen species-detonable nanoclusters designed for anti-restenotic therapy. The technology, assigned to the University of Virginia Patent Foundation, involves nanoclusters with self-assembled cores and biomimetic membrane coatings that can deliver anti-restenotic drugs.

USPTO Grants Patent for Bis-biguanide Compounds in Cancer Management

The USPTO has granted a patent (US12582618B2) to Emory University for bis-biguanide compounds and pharmaceutical compositions for managing cancer, particularly lung cancer. The patent covers methods of treatment and related compositions, with an effective grant date of March 24, 2026.

Bifunctional compounds for degrading BTK via ubiquitin pathway

The USPTO has granted patent US12582722B2 to Nurix Therapeutics, Inc. for bifunctional compounds designed to degrade Bruton's tyrosine kinase (BTK) through the ubiquitin proteolytic pathway. The patent covers novel compounds and pharmaceutical compositions for treating various diseases.